FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Romano Kathryn					2. Issuer Name and Ticker or Trading Symbol Krystal Biotech, Inc. [KRYS]								heck all app Direc	ationship of Reporting (all applicable) Director Officer (give title below) Chief Accou		10% Ov	vner	
(Last) (First) (Middle) C/O KRYSTAL BIOTECH, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/22/2024								^ belov			Other (s below) g Officer	specify	
2100 WHARTON STREET, SUITE 701				4. It	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) PITTSBURGH PA 15203														X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication														
					X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - No	n-Deriv	ative	Se	curit	ies Ac	quired	, Dis	posed o	of, or Be	eneficia	lly Owne	ed			
			2. Transaction Date (Month/Day/Year)		ar) Ē	2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Code (Instr.					d Securi Benefi Owned	. Amount of securities seneficially owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) o (D)	r Price	Repor Transa (Instr.	ed ction(s) 3 and 4)			(Instr. 4)	
Common Stock				01/22	2/2024				M ⁽¹⁾		2,500) A	\$52.	26 1	15,056		D	
Common Stock			01/22	2/2024			S ⁽¹⁾		2,500) D	\$130)(2) 1	2,556		D			
		T	able II -								osed of converti			y Owned	I			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	Code (In				6. Date E Expiratio (Month/D	n Date	•	le and 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$52.26	01/22/2024	01/22/2	2024	M ⁽¹⁾			2,500	(3)		01/30/2030	Common Stock	2,500	\$0	10,00	0	D	

Explanation of Responses:

- 1. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of \$130.00 per share.
- 2. The transaction was executed in one trade.
- 3. 50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021.

Remarks:

01/24/2024 /s/ Kathryn Romano

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.